Join our community of smart investors

The rationale for Roche

Despite being hit by Covid-19's disruption, the Swiss pharma giant offers a strong pipeline and shares with a reliable dividend
The rationale for Roche

Roche (ROG:CH) has been leading the charge on Covid-19 testing since the early days of the pandemic. Indeed, the Swiss healthcare giant has launched a number of specialist kits to detect the virus – from tests that reveal whether a patient is currently infected, to antibody tests that show whether someone has been infected. At the same time, the group is also working to fight the symptoms of the disease – it is currently monitoring the effectiveness of six different medicines across 28 clinical trials.  

IC TIP: Buy at 32,750CHF
Tip style
Growth
Risk rating
High
Timescale
Medium Term
Bull points

Tackling Covid-19 pandemic

Diversified revenue streams

Encouraging pipeline

Reliable dividend

Bear points

Hit by coronavirus disruption

Withholding tax complications

These efforts to tackle Covid-19 are testament to Roche’s leadership in the complementary fields of diagnostics and pharmaceuticals. Its bosses say that its in-house expertise in both domains puts it at the forefront of personalised care – working to “fit the right treatment to each patient in the best way possible”.

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in